Clinical Trial Update: Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating maintenance therapy with BGB-290 (pamiparib) versus placebo in platinum-sensitive recurrent ovarian cancer, and the study is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• BGB-290

Snippet

Sponsor: BeiGene | Conditions: Ovarian Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING